C. Melvin
Impact in
-
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
-
- Growth Hormone and Insulin-like Growth Factors
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 3
- Oncology 5
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 2
- Co-authors
- Antonio Gualberto (10 shared papers)Michaël Pollak (4 shared papers)David A. Chianese (1 shared paper)Johann S. de Bono (1 shared paper)Paul Haluska (2 shared papers)Alex A. Adjei (2 shared papers)Gerhardt Attard (1 shared paper)Madeline Repollet (1 shared paper)
- Journals
- Journal of Clinical Oncology (5 papers)Clinical Cancer Research (1 paper)Hematological Oncology (1 paper)Cancer Research (1 paper)Blood (1 paper)
- Partner nations
- United StatesCanadaSpain
In The Last Decade
C. Melvin
10 papers receiving 320 citations
Peers
Comparison fields: 5 of 41
- Cancer Research 139
- Endocrinology, Diabetes and Metabolism 148
- Oncology 150
- Hematology 33
- Molecular Biology 186
Countries citing papers authored by C. Melvin
This map shows the geographic impact of C. Melvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Melvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Melvin more than expected).
Fields of papers citing papers by C. Melvin
This network shows the impact of papers produced by C. Melvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Melvin. The network helps show where C. Melvin may publish in the future.
Co-authors
The 25 scholars most cited alongside C. Melvin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 152 | |
| 2 | 2008 | 122 | |
| 3 | 2007 | 32 | |
| 4 | Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors | 2007 | 7 |
| 5 | 2006 | 6 | |
| 6 | 2017 | 5 | |
| 7 | 2017 | 4 | |
| 8 | 2005 | 4 | |
| 9 | 2007 | 3 | |
| 10 | 2007 | 1 |
About C. Melvin
C. Melvin is a scholar working on Molecular Biology, Oncology, Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Hematology, having authored 10 papers that have together received 336 indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (5 papers), Cancer Treatment and Pharmacology (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Multiple Myeloma Research and Treatments (3 papers), Lung Cancer Treatments and Mutations (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Cancer Research (139 citations), Endocrinology, Diabetes and Metabolism (148 citations), Oncology (150 citations), Hematology (33 citations) and Molecular Biology (186 citations). C. Melvin has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Antonio Gualberto, Michaël Pollak, David A. Chianese, Johann S. de Bono, Paul Haluska, Alex A. Adjei, Gerhardt Attard, Madeline Repollet, Peter C.C. Fong and Leon W.M.M. Terstappen. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Hematological Oncology, Cancer Research and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.